Research programme: cancer therapy - CEPTYR

Drug Profile

Research programme: cancer therapy - CEPTYR

Alternative Names: CEPTYR 234; PTPx inhibitor; PTPxx; PTPy

Latest Information Update: 09 Jul 2007

Price : $50

At a glance

  • Originator CEPTYR
  • Class
  • Mechanism of Action Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jul 2004 Compounds from this research programme are available for licensing (
  • 30 Jul 2003 Preclinical development for Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top